MX2020010144A - Dosificación subcutánea de anticuerpos anti grupo de diferenciación 38 (cd38). - Google Patents
Dosificación subcutánea de anticuerpos anti grupo de diferenciación 38 (cd38).Info
- Publication number
- MX2020010144A MX2020010144A MX2020010144A MX2020010144A MX2020010144A MX 2020010144 A MX2020010144 A MX 2020010144A MX 2020010144 A MX2020010144 A MX 2020010144A MX 2020010144 A MX2020010144 A MX 2020010144A MX 2020010144 A MX2020010144 A MX 2020010144A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- subcutaneous dosing
- methods
- cancers
- dosage forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862649489P | 2018-03-28 | 2018-03-28 | |
| PCT/IB2019/000314 WO2019186273A1 (en) | 2018-03-28 | 2019-03-27 | Subcutaneous dosing of anti-cd38 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020010144A true MX2020010144A (es) | 2020-12-07 |
Family
ID=66647425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020010144A MX2020010144A (es) | 2018-03-28 | 2019-03-27 | Dosificación subcutánea de anticuerpos anti grupo de diferenciación 38 (cd38). |
Country Status (12)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| PE20171094A1 (es) | 2014-12-04 | 2017-08-07 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda |
| BR112017024877A2 (pt) | 2015-05-20 | 2019-09-17 | Janssen Biotech, Inc. | anticorpo anti-cd38 e seu uso no tratamento de amiloidose de cadeia leve e outras malignidades hematológicas positivas para cd38 |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| ES2912729T3 (es) | 2015-11-03 | 2022-05-27 | Janssen Biotech Inc | Formulaciones subcutáneas de anticuerpos anti-CD38 y sus usos |
| CN111565751A (zh) | 2017-10-31 | 2020-08-21 | 詹森生物科技公司 | 治疗高危多发性骨髓瘤的方法 |
| CN112513087B (zh) * | 2018-09-11 | 2023-01-24 | 江苏恒瑞医药股份有限公司 | 抗cd38抗体、其抗原结合片段及医药用途 |
| CA3116878A1 (en) * | 2018-10-17 | 2020-04-23 | Janssen Biotech, Inc. | Method of providing subcutaneous administration of anti-cd38 antibodies |
| EP4069743A1 (en) * | 2019-12-05 | 2022-10-12 | Sanofi-Aventis U.S. LLC | Formulations of anti-cd38 antibodies for subcutaneous administration |
| MX2022014297A (es) * | 2020-05-15 | 2023-02-09 | Takeda Pharmaceuticals Co | Administración del inhibidor de la enzima activadora (sae) del modificador similar a la ubiquitina pequeña (sumo) y anticuerpos anti cúmulo de diferenciación 38 (cd38). |
| EP4376869A1 (en) | 2021-07-28 | 2024-06-05 | Genentech, Inc. | Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of blood cancers |
| AU2022350815A1 (en) * | 2021-09-23 | 2024-05-02 | Sound Biopharmaceuticals Co. Ltd. | Cd38 monoclonal antibody and application thereof |
| AU2023412139A1 (en) * | 2022-12-21 | 2025-06-19 | Sound Biopharmaceuticals Co. Ltd. | Cd38 monoclonal antibody and use thereof |
| WO2024147934A1 (en) | 2023-01-06 | 2024-07-11 | Takeda Pharmaceutical Company Limited | Anti-cd38 antibodies for the treatment of autoimmune diseases |
| WO2025193746A1 (en) | 2024-03-12 | 2025-09-18 | Takeda Pharmaceutical Company Limited | Dosing regimens of anti-cd38 antibodies for treatment of subjects with immune thrombocytopenia |
| WO2025235919A1 (en) | 2024-05-09 | 2025-11-13 | Takeda Pharmaceutical Company Limited | Dosing regimens of anti-cd38 antibodies for treatment of subjects with immunoglobulin a nephropathy |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3720353B2 (ja) | 1992-12-04 | 2005-11-24 | メディカル リサーチ カウンシル | 多価および多重特異性の結合タンパク質、それらの製造および使用 |
| US6086875A (en) | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| IT1320715B1 (it) | 2000-10-19 | 2003-12-10 | Cselt Centro Studi Lab Telecom | Modulo generatore di circuiti per la decodifica di codiciconvoluzionali, metodo per la generazione di tale tipo di circuito e |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US7497862B2 (en) | 2001-08-03 | 2009-03-03 | Tyco Healthcare Group Lp | Tissue marking apparatus and method |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| CA2602375C (en) * | 2005-03-23 | 2018-07-24 | Genmab A/S | Antibodies against cd38 for treatment of multiple myeloma |
| EP2799451A1 (en) | 2005-05-24 | 2014-11-05 | MorphoSys AG | Generation and profiling of fully human HuCAL GOLD®-derived therapeutic antibodies specific for human CD38 |
| EP1931709B1 (en) | 2005-10-03 | 2016-12-07 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| MX373301B (es) * | 2013-10-31 | 2020-04-24 | Sanofi Sa | Anticuerpos anti-cd38 específicos para usarse para tratar cánceres humanos. |
| HRP20210552T1 (hr) * | 2015-05-13 | 2021-05-14 | Morphosys Ag | Liječenje multiplog mijeloma (mm) |
| ES2912729T3 (es) * | 2015-11-03 | 2022-05-27 | Janssen Biotech Inc | Formulaciones subcutáneas de anticuerpos anti-CD38 y sus usos |
| JP7316930B2 (ja) * | 2016-07-15 | 2023-07-28 | 武田薬品工業株式会社 | 形質芽細胞及び形質細胞枯渇療法に対する応答を評価するための方法及び材料 |
-
2019
- 2019-03-27 JP JP2020551797A patent/JP7526099B2/ja active Active
- 2019-03-27 WO PCT/IB2019/000314 patent/WO2019186273A1/en not_active Ceased
- 2019-03-27 EP EP19726474.0A patent/EP3774915A1/en active Pending
- 2019-03-27 KR KR1020207030604A patent/KR20210002499A/ko not_active Ceased
- 2019-03-27 KR KR1020257024758A patent/KR20250117714A/ko active Pending
- 2019-03-27 BR BR112020019710-6A patent/BR112020019710A2/pt unknown
- 2019-03-27 CA CA3095086A patent/CA3095086A1/en active Pending
- 2019-03-27 US US17/041,783 patent/US20210047427A1/en active Pending
- 2019-03-27 AU AU2019244478A patent/AU2019244478B2/en active Active
- 2019-03-27 MX MX2020010144A patent/MX2020010144A/es unknown
- 2019-03-27 CN CN201980032101.8A patent/CN112154156A/zh active Pending
- 2019-03-28 TW TW113121338A patent/TW202504926A/zh unknown
- 2019-03-28 TW TW108110990A patent/TWI847979B/zh active
-
2020
- 2020-10-22 CO CONC2020/0013252A patent/CO2020013252A2/es unknown
-
2023
- 2023-12-25 JP JP2023218600A patent/JP2024045121A/ja active Pending
-
2025
- 2025-10-29 AU AU2025259859A patent/AU2025259859A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20250117714A (ko) | 2025-08-05 |
| RU2020135062A3 (cg-RX-API-DMAC7.html) | 2022-04-28 |
| TW202504926A (zh) | 2025-02-01 |
| BR112020019710A2 (pt) | 2021-01-26 |
| JP2021519295A (ja) | 2021-08-10 |
| CO2020013252A2 (es) | 2020-11-10 |
| AU2019244478A1 (en) | 2020-11-12 |
| EP3774915A1 (en) | 2021-02-17 |
| CA3095086A1 (en) | 2019-10-03 |
| KR20210002499A (ko) | 2021-01-08 |
| JP7526099B2 (ja) | 2024-07-31 |
| AU2019244478B2 (en) | 2025-11-06 |
| US20210047427A1 (en) | 2021-02-18 |
| WO2019186273A1 (en) | 2019-10-03 |
| TW202003566A (zh) | 2020-01-16 |
| CN112154156A (zh) | 2020-12-29 |
| RU2020135062A (ru) | 2022-04-28 |
| JP2024045121A (ja) | 2024-04-02 |
| AU2025259859A1 (en) | 2025-11-27 |
| WO2019186273A4 (en) | 2019-12-19 |
| TWI847979B (zh) | 2024-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020013252A2 (es) | Dosificación subcutánea de anticuerpos anti-cd38 | |
| CO2020008561A2 (es) | Dosificación subcutánea de anticuerpos anti-cd38 | |
| MX2020010458A (es) | Conjugados de camptotecina-peptido. | |
| MX2020008977A (es) | Formulaciones de anticuerpos de her2 subcutaneas. | |
| CL2020003071A1 (es) | Proteínas de unión multiespecíficas y mejoras con estas | |
| CO2020016619A2 (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso | |
| EA202091134A1 (ru) | Экзосомы для иммуноонкологической и противовоспалительной терапии | |
| UY38236A (es) | COMBINACIONES FARMACÉUTICAS QUE CONTIENEN EL ANTICUERPO ANTI-CD38, ASOCIADO CON LOS ANTICUERPOS BIOESPECÍFICOS BCMAxCD3 O GPRC5DxCD3 O CD19xCD3 | |
| EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
| EA201890530A1 (ru) | Конъюгаты антитела к dll3 и лекарственного средства и способы их применения | |
| EA201892294A1 (ru) | Антитела и композиции против tim-3 | |
| DOP2018000026A (es) | Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes | |
| EA201791736A1 (ru) | Комбинированная терапия для лечения рака | |
| CR20210010A (es) | Anticuerpos dirigidos contra il-11ra | |
| EA201790932A1 (ru) | Дозировка и введение нефукозилированных анти-cd40 антител | |
| EA201891399A1 (ru) | Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний | |
| ZA202103867B (en) | Tubulysins and protein-tubulysin conjugates | |
| EA202092302A1 (ru) | Антитела к trem-1 и их применения | |
| EA201892284A1 (ru) | Комбинация антитела против cd20, селективного ингибитора pi3-киназы-дельта и ингибитора btk для лечения b-клеточных пролиферативных расстройств | |
| MX2020011027A (es) | Constructos de anticuerpos biespecíficos trivalentes. | |
| PH12020551968A1 (en) | Anti-sez6 antibody drug conjugates and methods of use | |
| EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
| EA201892265A1 (ru) | Способы лечения офтальмологических заболеваний | |
| EA201990370A1 (ru) | Терапия рака, связанная с crebbp | |
| EA202192488A1 (ru) | Антитела против tsg-6 и их применения |